Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1/2 Open Label Dose-escalation and Expansion Trial of NKT2152 an Orally Administered HIF2α Inhibitor to Investigate Safety Pharmacokinetics Pharmacodynamics and Clinical Activity in Patients With Advanced Clear Cell Renal Cell Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05119335
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:59.097773+00:00
Published At
2025-11-12T00:00:00+00:00
Record Updated At
2025-11-12
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["ccRCC", "Clear Cell Renal Cell Carcinoma", "Kidney Cancer", "Kidney Neoplasms", "Renal Cancer", "Renal Neoplasms", "Recurrent Renal Cell Carcinoma", "Metastatic Renal Cell Carcinoma", "Refractory Renal Cell Carcinoma", "Advanced Renal Cell Carcinoma", "Hypoxia", "Renal Cell Carcinoma", "Hypoxia Inducible Factor (HIF)", "HIF2\u03b1 Inhibitor", "Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha)", "Hypoxia Inducible Factor 2\u03b1 (HIF-2\u03b1)", "Clear Cell"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-11-12"
protocolSection.identificationModule.nctId
"NCT05119335"
protocolSection.identificationModule.officialTitle
"Phase 1/2 Open Label Dose-escalation and Expansion Trial of NKT2152 an Orally Administered HIF2\u03b1 Inhibitor to Investigate Safety Pharmacokinetics Pharmacodynamics and Clinical Activity in Patients With Advanced Clear Cell Renal Cell Carcinoma"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • ccRCC (protocolSection.conditionsModule.conditions)
  • Clear Cell Renal Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Kidney Cancer (protocolSection.conditionsModule.conditions)
  • Kidney Neoplasms (protocolSection.conditionsModule.conditions)
  • Renal Cancer (protocolSection.conditionsModule.conditions)
  • Renal Neoplasms (protocolSection.conditionsModule.conditions)
  • Recurrent Renal Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Renal Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Refractory Renal Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Advanced Renal Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Hypoxia (protocolSection.conditionsModule.conditions)
  • Renal Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Hypoxia Inducible Factor (HIF) (protocolSection.conditionsModule.conditions)
  • HIF2α Inhibitor (protocolSection.conditionsModule.conditions)
  • Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha) (protocolSection.conditionsModule.conditions)
  • Hypoxia Inducible Factor 2α (HIF-2α) (protocolSection.conditionsModule.conditions)
  • Clear Cell (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.